Pre-Clinical In Vitro Models Used in Cancer Research: Results of a Worldwide Survey

被引:27
作者
Martinez-Pacheco, Sarai [1 ,2 ,3 ]
O'Driscoll, Lorraine [1 ,2 ,3 ]
机构
[1] Trinity Coll Dublin, Panoz Inst, Sch Pharm & Pharmaceut Sci, Dublin D02 PN40, Ireland
[2] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin D02 R590, Ireland
[3] Trinity Coll Dublin, Trinity St Jamess Canc Inst, Dublin D08 NHY1, Ireland
基金
欧盟地平线“2020”;
关键词
cancer; in vitro models; 3D culture; 3Rs; methodology; survey; precision medicine; 3-DIMENSIONAL CELL-CULTURE; EXTRACELLULAR-MATRIX; ADVANTAGES; SCAFFOLDS; SYSTEMS;
D O I
10.3390/cancers13236033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Cancer cell lines, grown on plastic dishes i.e., two-dimensional (2D), are routinely used in cancer research, e.g., when evaluating the effectiveness of potential anti-cancer drugs before proceeding to studies in animal models and then human clinical trials. Stop/go decisions are generally made from these initial studies. As only ~10% of potential anti-cancer drugs succeed during clinical development, this suggests that these models are inadequate. Cells grown as three-dimensional (3D) models, akin to a tumor mass and with other cells that would naturally occur in its environment, should be more clinically relevant. We performed a worldwide survey, open to cancer researchers at all stages and in all settings, to find out what models they use; for what purposes, and why they chose those models. The majority reported using 2D models only, mainly due to lack of experience and costs but expressed interest in 3D cultures. Guidelines on how to develop such models cost-effectively are needed. To develop and subsequently get cancer researchers to use organotypic three-dimensional (3D) models that can recapitulate the complexity of human in vivo tumors in an in vitro setting, it is important to establish what in vitro model(s) researchers are currently using and the reasons why. Thus, we developed a survey on this topic, obtained ethics approval, and circulated it throughout the world. The survey was completed by 101 researchers, across all career stages, in academia, clinical or industry settings. It included 40 questions, many with multiple options. Respondents reported on their field of cancer research; type of cancers studied; use of two-dimensional (2D)/monolayer, 2.5D and/or 3D cultures; if using co-cultures, the cell types(s) they co-culture; if using 3D cultures, whether these involve culturing the cells in a particular way to generate spheroids, or if they use additional supports/scaffolds; techniques used to analyze the 2D/2.5D/3D; and their downstream applications. Most researchers (>66%) only use 2D cultures, mainly due to lack of experience and costs. Despite most cancer researchers currently not using the 3D format, >80% recognize their importance and would like to progress to using 3D models. This suggests an urgent need to standardize reliable, robust, reproducible methods for establishing cost-effective 3D cell culture models and their subsequent characterization.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The opinion of general practitioners on the treatment of prostate and breast cancer in elderly people: Results of a survey based on clinical models
    Votron, L
    D'Hoore, W
    Swine, C
    Daisne, JF
    Scalliet, P
    CLINICAL ONCOLOGY, 2004, 16 (07) : 474 - 478
  • [42] 99mTc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications
    Barboza, Thiago
    Gomes, Taina
    Mizurini, Daniella M.
    Monteiro, Robson Q.
    Koenig, Sandra
    Francischetti, Ivo M. B.
    Signoretti, Paula V. P.
    Ramos, Isalira P.
    Gutfilen, Bianca
    Souza, Sergio A. L.
    THROMBOSIS RESEARCH, 2015, 136 (02) : 432 - 439
  • [43] Is adjuvant tamoxifen used optimally in the treatment of breast cancer? Results of an Italian survey
    Valentini, M
    Mari, E
    Belfiglio, M
    Nicolucci, A
    ANNALS OF ONCOLOGY, 1999, 10 (07) : 789 - 793
  • [44] Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology
    Conway, James R. W.
    Vennin, Claire
    Cazet, Aurelie S.
    Herrmann, David
    Murphy, Kendelle J.
    Warren, Sean C.
    Wullkopf, Lena
    Boulghourjian, Alice
    Zaratzian, Anaiis
    Da Silva, Andrew M.
    Pajic, Marina
    Morton, Jennifer P.
    Cox, Thomas R.
    Timpson, Paul
    SCIENTIFIC REPORTS, 2017, 7
  • [45] Cancer researchers' experiences with and perceptions of research data sharing: Results of a cross-sectional survey
    Hamilton, Daniel G.
    Page, Matthew J.
    Everitt, Sarah
    Fraser, Hannah
    Fidler, Fiona
    ACCOUNTABILITY IN RESEARCH-ETHICS INTEGRITY AND POLICY, 2024, : 530 - 557
  • [46] Attitude towards clinical trials: Results of a survey of persons interested in research
    Ohmann, C
    Deimling, A
    INFLAMMATION RESEARCH, 2004, 53 (Suppl 2) : S142 - S147
  • [47] Attitude towards clinical trials: Results of a survey of persons interested in research
    C. Ohmann
    A. Deimling
    Inflammation Research, 2004, 53 : S142 - S147
  • [48] Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic
    Reddy, Joseph A.
    Dorton, Ryan
    Bloomfield, Alicia
    Nelson, Melissa
    Dircksen, Christina
    Vetzel, Marilynn
    Kleindl, Paul
    Santhapuram, Hari
    Vlahov, Iontcho R.
    Leamon, Christopher P.
    SCIENTIFIC REPORTS, 2018, 8
  • [49] Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios
    Aktar, Rozina
    Dietrich, Antje
    Tillner, Falk
    Kotb, Shady
    Loeck, Steffen
    Willers, Henning
    Baumann, Michael
    Krause, Mechthild
    Buetof, Rebecca
    BRITISH JOURNAL OF RADIOLOGY, 2019, 92 (1095)
  • [50] Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients
    de las Heras, Begona
    Daehnke, Adam
    Saini, Kamal S.
    Harris, Melissa
    Morrison, Kenneth
    Aguilo, Ariel
    Chico, Isagani
    Vidal, Laura
    Marcus, Robin
    DIGITAL HEALTH, 2022, 8